|Bid||24.30 x 1000|
|Ask||24.73 x 1800|
|Day's Range||24.01 - 25.36|
|52 Week Range||1.94 - 25.80|
|Beta (3Y Monthly)||3.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2019 - Aug 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.60|
NEW YORK, May 21, 2019 -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous.
This startup has rapidly developed two potential blockbusters that are close to the finish line, and hardly anybody's noticed yet.
On a per-share basis, the New York-based company said it had a loss of 32 cents. Axsome shares have increased sixfold since the beginning of the year. The stock has risen fivefold in the last 12 months. ...
Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2019. “The first five months of 2019 have been highly productive at Axsome as we advanced our mission to develop innovative medicines for patients living with serious and difficult-to-treat CNS disorders. “We also received Breakthrough Therapy designation from the FDA for AXS-05 for the treatment of major depressive disorder, and recently announced, based on the Breakthrough Therapy meeting, an expedited clinical development plan for AXS-05 in depression which could result in a potential NDA filing for AXS-05 in 2020.
Axsome Therapeutics Inc. (AXSM) gained 39 cents to $19.54 on Tuesday on 1.4 million shares traded. The biotech company announced Monday that the FDA granted breakthrough therapy designation for a major depressive disorder treatment. It’s now right at lateral resistance, a break through which could lead to the $20 range short-term.
Here are four stocks to watch with strong technical momentum fueled by earnings and other news. Axsome Therapeutics, Inc. (NASDAQ: AXSM ) gained 39 cents to $19.54 on Tuesday on 1.4 million shares. The ...
Fuel Tech's (FTEK) Q1 results are likely to benefit from increased adoption of emission control solutions, efforts to improve sales channel and addition of a coal-fired unit in the United States.
On Axsome's (AXSM) first-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.
Axsome Therapeutics Inc (NASDAQ: AXSM) has been a standout performer among biotech stocks year-to-date. Axsome announced Monday that the FDA granted Breakthrough Therapy Designation for its AXS-05, which is being evaluated for major depressive disorder, or MDD, and treatment-resistant depression, or TRD. With the expedited development program, the company said its previously completed ASCEND Phase 2 trial is adequate to file an NDA for MDD.
Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the acceleration of the timeline for reporting topline results from the MOMENTUM Phase 3 trial of AXS-07 (MoSEIC™ meloxicam and rizatriptan), Axsome’s novel, oral, investigational medicine with distinct dual mechanisms of action for the acute treatment of migraine. The trial is being conducted pursuant to a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA).
Previously completed active-controlled ASCEND trial in MDD now considered as pivotal; sufficient with ongoing STRIDE-1 Phase 3 trial for NDA in MDD Target randomization for.
Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter of 2019 on Thursday, May 9, 2019 before the opening of the U.S. financial markets.
Axsome Therapeutics and PhaseBio Pharmaceuticals are soaring this year, but the best could be yet to come for each of these red-hot biotech stocks.
Axsome's (AXSM) mid-stage candidate, AXS-05, achieves the primary endpoint in a phase II study as a smoking cessation treatment. Shares rise.
Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Duke University has completed its topline analysis of the Phase 2 trial of AXS-05 for smoking cessation treatment. The analysis showed that AXS-05 met the prespecified primary endpoint and significantly reduced daily smoking as compared to the active comparator bupropion. The trial was conducted at the Duke Center for Smoking Cessation under a research collaboration between Axsome and Duke University.
Investors need to pay close attention to Axsome Therapeutics (AXSM) stock based on the movements in the options market lately.
Biogen threw in the towel with once-promising Alzheimer's disease drug aducanumab. But these three late-stage pipeline candidates could potentially still emerge as winners.
Axsome (AXSM) announces that the FDA has granted Breakthrough Therapy designation to AXS-05 for the treatment of major depressive disorder (MDD).